

Definition of a discontinuous immunodominant epitope at the NH2 terminus of the La/SS-B ribonucleoprotein autoantigen.

L J McNeilage, ... , S Whittingham, T Gordon

J Clin Invest. 1992;**89**(5):1652-1656. <https://doi.org/10.1172/JCI115762>.

Research Article

High-titer IgG autoantibodies to the La/SS-B ribonucleoprotein (RNP) are a hallmark of patients with primary Sjogren's syndrome. Anti-La/SS-B-positive human sera bind to multiple epitopes on recombinant La/SS-B, although the initial response is against an immunodominant epitope within the first 107 NH2-terminal amino acids (aa). Sequence analysis has identified a striking homology between aa 88-101 in this NH2-terminal region of La/SS-B and a feline retroviral gag polypeptide suggesting the anti-La/SS-B response may be initiated by cross-reactivity with an exogenous agent. In the present study, detailed mapping of this NH2-terminal epitope, using recombinant La/SS-B purified from the expression of overlapping DNA fragments spanning aa 1-107, has shown that this immunodominant epitope is a complex conformational or discontinuous epitope dependent upon both aa 12-28 and 82-99 for expression, even though these regions share no homology with each other. This requirement questions the significance of the homology between La/SS-B and a retroviral gag polypeptide in the generation of the B cell response to La/SS-B and is in accord with the general concept that B cells recognize conformational epitopes on antigens rather than small linear peptide sequences. The finding also reinforces the notion that native autoantigen could be the initiator of the autoimmune response.

Find the latest version:

<https://jci.me/115762/pdf>



Definition of a Discontinuous Immunodominant Epitope at the NH₂ Terminus of the La/SS-B Ribonucleoprotein Autoantigen

L. Jane McNeilage,* Kandiah Umapathysivam,† Elizabeth Macmillan,‡§ Angelo Guidolin,* Senga Whittingham,¶ and Tom Gordon*

*Department of Clinical Immunology, Flinders Medical Centre, Bedford Park, South Australia 5042; †Rheumatology Research Unit, Repatriation General Hospital, Daw Park, South Australia 5042; ‡Burnet Clinical Research Unit, The Walter and Eliza Hall Institute, Royal Melbourne Hospital, Victoria 3050, Australia

Abstract

High-titer IgG autoantibodies to the La/SS-B ribonucleoprotein (RNP) are a hallmark of patients with primary Sjogren's syndrome. Anti-La/SS-B-positive human sera bind to multiple epitopes on recombinant La/SS-B, although the initial response is against an immunodominant epitope within the first 107 NH₂-terminal amino acids (aa). Sequence analysis has identified a striking homology between aa 88-101 in this NH₂-terminal region of La/SS-B and a feline retroviral gag polypeptide suggesting the anti-La/SS-B response may be initiated by cross-reactivity with an exogenous agent. In the present study, detailed mapping of this NH₂-terminal epitope, using recombinant La/SS-B purified from the expression of overlapping DNA fragments spanning aa 1-107, has shown that this immunodominant epitope is a complex conformational or discontinuous epitope dependent upon both aa 12-28 and 82-99 for expression, even though these regions share no homology with each other. This requirement questions the significance of the homology between La/SS-B and a retroviral gag polypeptide in the generation of the B cell response to La/SS-B and is in accord with the general concept that B cells recognize conformational epitopes on antigens rather than small linear peptide sequences. The finding also reinforces the notion that native autoantigen could be the initiator of the autoimmune response. (*J. Clin. Invest.* 1992. 89:1652-1656.) Key words: autoantibody • anti-La/SS-B • epitope mapping • molecular mimicry

Introduction

The application of recombinant DNA technology to the study of autoantibodies to nuclear antigens (ANA)¹ has been an important tool in the analysis of the possible mechanisms of ANA production. The three main theories proposed for autoantibody production have been polyclonal B cell activation (1, 2),

Address reprint requests to Dr. L. J. McNeilage, Department of Clinical Immunology, Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia. Elizabeth Macmillan's present address is Hanson Centre for Cancer Research, The Institute of Medical and Veterinary Research, Frome Road, Adelaide, South Australia 5000.

Received for publication 21 October 1991 and in revised form 31 December 1991.

1. Abbreviations used in this paper: aa; amino acid, ANA; antinuclear antibody, GST; glutathione-S-transferase, RNP; ribonuclear protein.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/92/05/1652/07 \$2.00

Volume 89, May 1992, 1652-1656

molecular mimicry with self (3, 4), and a response initiated and maintained by self (5, 6). While evidence for polyclonal B cell activation exists for some autoantibody responses (1), a number of studies utilizing recombinant nuclear autoantigens (7-16) have provided strong evidence that ANA responses are induced and maintained by self antigen.

There is well established evidence for molecular mimicry between autoantigens and microbial antigens in autoimmune myocarditis. Cross-reactivity has been demonstrated between cardiac antigens and the group A β -hemolytic *Streptococcus* (17) and cardiac and peripheral nerve antigens and *Trypanosoma cruzi* (18, 19). Molecular mimicry may also account for the induction of ANA. For example, Query and Keene (20) identified an epitope in the 70-kD protein of the U1 small nuclear ribonucleoprotein (snRNP) with homology to the retroviral p30^{gag} protein which they suggested initiated the anti-U1 RNP antibody response. In support of this Cram et al. (15) showed a higher frequency (72% compared with 58%) of antibodies to a recombinant 70-kD U1 RNP protein containing the cross-reactive epitope in newly diagnosed patients with mixed connective tissue disease than in patients with established disease. More recently, Maul et al. (21) identified an epitope on DNA topoisomerase 1 with homology to the retroviral p30^{gag} protein separated by only one amino acid from the region of the p30^{gag} homologous to the 70-kD U1 RNP epitope. A role for virus in the initiation of the autoantibody response to U1 RNP has also been suggested by reactivity of U1 RNP-positive sera with a U1 RNP peptide (ERKRR) with homology to the M1 matrix protein of influenza B viruses (22). Two further studies have highlighted the potential for molecular mimicry in ANA induction. In the first, Kohsaka et al. (23) demonstrated a striking homology (six out of eight consecutive amino acids) between an epitope (aa 88-101) on the La/SS-B ribonucleoprotein (RNP) autoantigen and a viral gag protein. In the second, Garry (24) showed that immunodominant epitopes of the human immunodeficiency virus (HIV) capsid protein are found in regions with homology to epitopes in several autoantigens, including the NH₂-terminal epitope on (aa 88-101) La/SS-B identified by Kohsaka et al. (23). Furthermore, analysis of the reactivity of serial serum samples from three patients with anti-La/SS-B (16) showed that the autoantibody response to La/SS-B was initially directed to an immunodominant NH₂-terminal epitope (aa 1-107) and later over a period of time to other regions of La/SS-B.

The present study examined the nature of the immunodominant NH₂-terminal epitope by employing the polymerase chain reaction (PCR) to generate six overlapping DNA fragments encompassing the NH₂-terminal 107 amino acids of La/SS-B (Fig. 1 A). Measurement of the level of binding of a pool of 10 anti-La/SS-B positive sera to the recombinant La/SS-B

proteins produced by expression of the six DNA fragments demonstrated that two separate regions must be present for binding to occur.

Methods

Derivation of DNA encoding overlapping regions of the N-terminal 107 amino acids of the human La/SS-B autoantigen by PCR. Six DNA fragments encoding the NH₂-terminal 107 aa of the La/SS-B polypeptide were derived by PCR (25). The primers were synthesized on the basis of the published human La/SS-B sequence (26), with the addition of a BamH1 site and an EcoR1 site on the 5' and 3' oligonucleotides, respectively. The amplification was performed for 15 cycles, with each cycle being 1.5 min at 95°C, 2 min at 45°C, and 2 min at 72°C. The amplified fragments were purified on low melting-temperature agarose.

Expression of PCR-generated La/SS-B DNA fragments. Each La/SS-B DNA fragment was subcloned into the pGEX-2 vector (27) to generate in-frame fusions with the COOH-terminus of glutathione-S-transferase (GST). Transformants were analyzed for recombinant protein production (27), and sequenced to confirm in-frame gene fusions. Recombinant proteins from the six different NH₂-terminal subclones, LaA₁-A₆, were purified (27) and analyzed by SDS-PAGE (28) to verify purity. The recombinant protein bands were identified either by staining the gels with Coomassie blue or by immunoblotting (29) using a polyclonal rabbit anti-GST serum (a gift from C. Davern, The Walter and Eliza Hall Institute for Medical Research). The latter reaction was visualized with a horseradish peroxidase-conjugated sheep anti-rabbit IgG (Silenus, Melbourne, Australia) and enhanced chemiluminescence (Amersham International, Amersham, UK).

DNA sequencing. DNA isolated from the LaA₁-A₆ subclones was sequenced in the pGEX-2 expression vector directly by the dideoxy chain termination method (30) with an alkali-denatured double-stranded template and two primers, designed to anneal 5' (5'-GCATGGCCTTGCAGGG-3') and 3' (5'-CATCACCGAAACGCGC-G-3'), to the pGEX-2 cloning site (16).

Protein determination. The concentration of the purified recombinant La/SS-B-GST proteins was determined by the Lowry protein assay (31) using GST as the standard.

ELISA. Microtiter wells were coated with purified recombinant La/SS-B or GST at a concentration of 0.7 µg/ml in 0.03 M sodium carbonate, pH 9.6, and incubated overnight at 4°C. After blocking for 2 h with 3% BSA in 0.01 M phosphate buffered, 0.15 M saline, pH 7.4 (PBS), the wells were washed three times with PBS-0.05% Tween 20 (Sigma Chemical Co., St. Louis, MO; PBS-Tween) and incubated at 37°C for 1 h with 0.1-ml dilutions of anti-La/SS-B positive sera or sera from healthy controls in 3% BSA-PBS-Tween. After four washes with PBS-Tween, 0.1 ml of an alkaline-phosphate conjugated goat anti-human IgG (Sigma Chemical Co.) was added to each well and incubated for 2 h at 37°C. After four washes with PBS-Tween, each well was incubated with substrate (*p*-nitrophenyl phosphate in diethanolamine, Sigma Chemical Co.) and the optical density at 405 nm (OD₄₀₅) monitored using a microtiter plate reader (Bio-Rad Laboratories, Richmond, CA).

Measurement of the immunoreactivity of the GST component of each recombinant La/SS-B protein was used to assess its relative adherence to polystyrene wells. Sequential fourfold dilutions of a rabbit polyclonal anti-GST serum were reacted with each of the recombinant La/SS-B-GST proteins, and binding was determined by ELISA using an alkaline phosphatase conjugated anti-rabbit IgG (Sigma Chemical Co.).

In competition ELISAs, sera were first preincubated in the presence or absence of inhibitor for 1 h at room temperature and then added to antigen-coated wells that had been blocked with 3% BSA-PBS. Following a 1-h incubation step, the remainder of the ELISA was performed as described above. The percent inhibition equaled (OD₄₀₅ without inhibitor-OD₄₀₅ with inhibitor)/(OD₄₀₅ without inhibitor) × 100.

Human sera. The 10 anti-La/SS-B positive sera used in this study were derived from the Diagnostic Immunology Laboratory at the Flinders Medical Centre. They were positive for anti-La/SS-B by counterimmunoelectrophoresis and reacted with full-length recombinant La/SS-B (16) by ELISA. 42 sera from healthy individuals were used as controls.

Results

Reactivity of anti-La/SS-B-positive sera with LaA₁₋₆ fusion proteins. The 7 regions of the 5' coding portion of the La/SS-B gene derived by PCR and subcloned into the pGEX-2 expression vector to generate in-frame fusions with GST are defined in Fig. 1 A. All 7 subclones produced stable recombinant proteins of the expected M_r with little evidence of degradation as illustrated by Coomassie blue staining (Fig. 1 B). The clone containing the LaA₄ fragment produced 5–10-fold more recombinant protein/liter of culture than the other LaA subclones.

Fig. 2 shows a representative immunoblot of the LaA₁₋₆ recombinant proteins probed with a polyclonal rabbit anti-GST serum (A) and a pool of 10 anti-La/SS-B-positive sera (B). The anti-La/SS-B-positive sera reacted only with LaA (aa 1-107), LaA₁ (aa 12-107) and LaA₄ (aa 1-99). Serum from a healthy control did not react with any of the LaA₁₋₆ fusion proteins (data not shown).

Table I shows the OD_{405nm} obtained when the 10 anti-La/SS-B positive sera were tested individually for reactivity to the LaA₁₋₆ recombinant proteins by ELISA. Among the 10 sera,




Figure 1. (A) Schematic diagram of the PCR-derived LaA and LaA₁₋₆ fragments subcloned into the pGEX-2 expression vector (27). The region of the protein encoded by each fragment is given by the amino acid (aa) numbers and the two regions required for expression of the immunodominant epitope within LaA are represented by the shaded areas. (B) Coomassie blue stain of the affinity-purified recombinant LaA₁₋₆ proteins separated by SDS-PAGE. Molecular weight standards are shown in the first lane.




Figure 2. Immunoblot showing reactivity of a polyclonal rabbit anti-GST serum (A) and a pool of 10 anti-La/SS-B-positive sera (B) with the recombinant LaA proteins and GST.

the mean optical densities ($OD_{405\text{nm}} \pm$ standard deviation) were: LaA, 1.27 (± 0.29); LaA₁ 1.10 (± 0.21); LaA₂ 0.003 (± 0.001); LaA₃ 0.01 (± 0.01); LaA₄ 1.19 (± 0.33); LaA₅, 0.01 (± 0.01); and LaA₆ 0.01 (± 0.01). The mean $OD_{405\text{nm}}$ values of the anti-La/SS-B-positive sera were significantly greater than controls reacted with recombinant LaA₁ and LaA₄ but did not differ significantly from controls reacted with recombinant LaA₂, A₃, A₅, or A₆. The ELISA results for the individual anti-La/SS-B-positive sera confirm the pattern of reactivity seen on the immunoblot (Fig. 2 B) with the pooled anti-La/SS-B-positive sera.

The direct comparison of levels of antibody binding to the different LaA₁₋₆ recombinant proteins assumes adherence of each to the solid phase. This was tested by measuring the immunoreactivity of the GST component of each recombinant protein. At an antigen coating concentration of 0.7 $\mu\text{g/ml}$ sequential dilutions of a polyclonal rabbit anti-GST serum reacted strongly with LaA and each of the recombinant LaA₁₋₆ proteins although binding to LaA₂ and LaA₃ was lower than to the other recombinant proteins (Fig. 3). Despite doubling of the coating concentration for LaA₂ and LaA₃ the pooled anti-La/SS-B-

Table I. Direct Binding of Anti-La/SS-B-positive Sera to Recombinant LaA₁₋₆ by ELISA

Patients	Binding (expressed as $OD_{405\text{nm}}$) to						
	LaA	LaA ₁	LaA ₂	LaA ₃	LaA ₄	LaA ₅	LaA ₆
1	1.06	0.66	0.01	0.01	0.83	0.03	0
2	1.28	1.17	0.01	0.02	1.15	0.09	0.04
3	1.39	1.21	0	0.01	1.52	0.01	0
4	1.16	0.87	0	0	0.72	0.03	0.01
5	1.43	1.21	0	0	1.29	0.02	0
6	1.43	1.21	0	0	1.12	0.04	0
7	0.75	1.17	0	0.01	1.06	0	0
8	1.85	1.35	0.01	0.01	1.90	0	0
9	1.06	0.97	0	0	1.15	0.02	0.02
10	1.29	1.21	0	0	1.16	0.04	0.01
Mean	1.27	1.10	0.003	0.01	1.19	0.01	0.01
SD	0.29	0.21	0.001	0.01	0.33	0.01	0.01
Healthy controls							
Mean	0.02	0.04	0.02	0.05	0.03	0.10	0.08
SD	0.01	0.03	0.02	0.03	0.01	0.05	0.06




Figure 3. Analysis of recombinant LaA₁₋₆ protein adherence to the solid phase by reactivity with a polyclonal rabbit anti-GST serum. Each of the recombinant LaA₁₋₆ proteins was coated onto microtiter wells at 0.7 $\mu\text{g/ml}$ and reacted by ELISA with sequential dilutions of the rabbit anti-GST serum. The binding of the rabbit anti-GST serum to the recombinant proteins is given by the $OD_{405\text{nm}}$.

positive sera still failed to react with either of these recombinant proteins (data not shown). These results suggest that each of the LaA subfragments adhered effectively to microtiter wells and that failure to detect binding of anti-La/SS-B positive sera to the LaA_{2,3,5} and A₆ subfragments was not due to poor coating of antigen.

Competitive inhibition of antibody binding to LaA by the LaA₁ and LaA₄ subfragments. Preincubation of the pooled anti-La/SS-B-positive sera with different concentrations of recombinant LaA, LaA₁ and LaA₄ proteins significantly reduced the level of anti-La/SS-B binding to LaA (Table II). In contrast,

Table II. Inhibition of Anti-La/SS-B Binding to Recombinant LaA Proteins

Inhibitor*	mg/ml	% Reduction in anti-La/SS-B binding to		
		LaA	LaA ₁	LaA ₄
LaA ₁	10	99	98	99
	1	99	96	97
	0.1	96	42	75
	0.01	49	13	36
LaA ₄	10	100	96	99
	1	85	58	84
	0.1	52	16	33
	0.01	42	10	16
LaA ₃	10	34	NT [§]	NT
	1	30	NT	NT
	0.1	24	NT	NT
	0.01	30	NT	NT
GST [‡]	10	24	NT	NT
	1	20	NT	NT
	0.1	24	NT	NT
	0.01	24	NT	NT

* The pooled anti-La/SS-B sera were incubated with different concentrations of inhibitors for 1 h at room temperature. [‡] A similar reduction in binding was seen with recombinant LaA₂, LaA₅, and LaA₆. [§] NT, not tested.

preincubation of the pooled sera with different concentrations of recombinant LaA₂, LaA₃, LaA₅, and LaA₆ proteins failed to substantially alter the level of anti-La/SS-B binding to LaA (Table II). A lack of inhibition by GST alone (Table II) confirms that antibodies in the anti-La/SS-B positive sera react with sequences in the La/SS-B portion of the recombinant proteins and not with the GST moiety.

Discussion

This study has used recombinant human La/SS-B proteins comprising six overlapping regions of the NH₂-terminal 107 amino acids of the La/SS-B autoantigen to further define the immunodominant epitope contained within this region of La/SS-B. This data is in apparent contrast to that obtained by Kohsaka et al. (23) who mapped the immunodominant NH₂-terminal epitope to amino acids 88-101. However, Kohsaka et al. (23) used overlapping fragments derived only by 3' deletions of the La/SS-B cDNA, in contrast to the overlapping fragments used in the present study which contained both 5' and 3' deletions. Use of recombinant proteins expressed by subfragments LaA₁, LaA₂, and LaA₃, all of which contain 5' deletions (Fig. 1 A), has revealed the requirement for amino acids 12-28 in formation of the NH₂-terminal epitope. This is supported by data from an earlier study (9) showing that a La/SS-B fragment encoding amino acids 54-137 was not immunoreactive. Furthermore anti-La/SS-B binding was detected to only two of the six recombinant proteins, LaA₁ (aa 12-107) and LaA₄ (aa 1-99), and these were the only two proteins to inhibit binding to recombinant LaA (aa 1-107). These data, together with the fact that the two regions, amino acids 12-28 and 82-99, are only present in LaA₁ and LaA₄, suggest that the immunodominant NH₂-terminal epitope on La/SS-B is a discontinuous or conformational epitope requiring amino acids 12-28 and 82-99 for expression.

Identification of a discontinuous or conformation-dependent epitope in the region of La/SS-B to which the anti-La/SS-B response may be initiated (16) raises questions about the significance of the homology identified (23) between amino acids 88-101 of La/SS-B and amino acids 22-50 of a feline sarcoma virus gag polypeptide. It would seem unlikely that an isolated region of sequence similarity in a viral gag protein could mimic a complex conformational determinant involving disparate regions of a self antigen. However, whereas the data imply that anti-La/SS-B recognizes the retroviral sequence in La alone it may also recognize that sequence in conjunction with a different region on the retrovirus. This implies that the two hypotheses for the generation of autoantibodies, molecular mimicry and anti-self may not be mutually exclusive. The demonstration of direct binding of anti-La/SS-B to the relevant retroviral protein will be important in further elucidation of these mechanisms. Furthermore, it cannot be discounted that such linear regions of similarity between self and viral antigens may be of more importance in the loss of T cell tolerance to autoantigens. Homologies between epitopes on other nuclear autoantigens and viral proteins have been reported previously (20-22, 24) and while it is possible that infection with a virus could induce the production of antibodies that react with a limited number of autoepitopes, this mechanism does not entirely explain the generation of an autoimmune response that is directed against multiple epitopes on the nuclear autoantigen

(7-16), some of which are conformational. Indeed conformation-dependent epitopes have been identified on a number of autoantigens (14, 32-36) and may be formed by amino acid residues from two or more regions of the molecule being brought into proximity to one another by protein folding (36). It should be noted that Geysen et al. (37) have shown that a linear hexapeptide with the correct stereochemistry could substitute for an epitope composed of three separate regions of a foot and mouth disease viral antigen. A similar analysis for the immunodominant NH₂-terminal La epitope will be important in further defining reactivity to this epitope.

Acknowledgments

We thank Associate Professor J. McCluskey for comments on the manuscript and Michelle Barker for typing the manuscript.

This work was supported by grants from the National Health and Medical Research Council of Australia and the Department of Veterans Affairs, Australia.

References

1. Hang, L., J. H. Slack, C. Amundson, S. Izui, A. N. Theofilopoulos, and F. Dixon. 1983. Induction of murine autoimmune disease by chronic polyclonal B cell activation. *J. Exp. Med.* 157:874-883.
2. Klinman, D. M., and A. D. Steinberg. 1987. Systemic autoimmune disease arises from polyclonal B cell activation. *J. Exp. Med.* 165:1744-1760.
3. Walker, E. J., and P. D. Jeffrey. 1986. Polymyositis and molecular mimicry, a mechanism of autoimmunity. *Lancet.* ii:605-607.
4. Oldstone, M. B. A. 1987. Molecular mimicry and autoimmune disease. *Cell.* 50:819-820.
5. Steinberg, A. D., H. R. Smith, C. A. Laskin, B. J. Steinberg, and J. S. Smolen. 1983. Studies of immune abnormalities in SLE. In *Advances in SLE*. J. A. Hardin and J. P. Hayslett, editors. Grune and Stratton, New York. 5-15.
6. Tan, E. M., E. K. L. Chan, K. F. Sullivan, and R. L. Rubin. 1988. Antinuclear antibodies (ANA): diagnostically specific immune markers and clues towards the understanding of systemic autoimmunity. *Clin. Immunol. Immunopathol.* 47:121-141.
7. Elkon, K. B., S. Skelly, A. Parnassa, W. Moller, W. Danho, H. Weissbach, and N. Brot. 1986. Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. *Proc. Natl. Acad. Sci. USA.* 83:7419-7423.
8. Earnshaw, W. C., K. F. Sullivan, P. S. Macklin, C. A. Cooke, D. A. Kaiser, T. D. Pollard, N. F. Rothfield, and D. W. Cleveland. 1987. Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen. *J. Cell Biol.* 104:817-829.
9. Sturgess, A. D., M. G. Peterson, L. J. McNeilage, S. Whittingham, and R. L. Coppel. 1988. Characteristics and epitope mapping of a cloned human autoantigen La. *J. Immunol.* 140:3212-3218.
10. Guldner, H. H., H. J. Netter, C. Stostecki, H. J. Lakomek, and H. Will. 1988. Epitope mapping with a recombinant 68-kDa (U1) ribonucleoprotein antigen reveals heterogeneous autoantibody profiles in human autoimmune sera. *J. Immunol.* 141:469-475.
11. St. Clair, E. W., D. S. Pisetsky, C. F. Reich, and J. D. Keene. 1988. Analysis of autoantibody binding to different regions of the human La antigen expressed in recombinant fusion proteins. *J. Immunol.* 141:4173-4180.
12. Rauh, A. J. G., H. Hornig, and R. Luhrmann. 1988. At least 3 distinct B cell epitopes reside in the C-terminal half of La protein, as determined by a recombinant DNA approach. *Eur. J. Immunol.* 18:2049-2057.
13. Bini, P., J. L. Chu, C. Okolo, and K. Elkon. 1990. Analysis of autoantibodies to recombinant La (SS-B) peptides in systemic lupus erythematosus and primary Sjogren's syndrome. *J. Clin. Invest.* 85:325-333.
14. Habets, W. J., M. J. Hoet, and W. J. van Venrooij. 1990. Epitope patterns of anti-RNP antibodies in rheumatic diseases. Evidence for an antigen-driven autoimmune response. *Arthritis Rheum.* 33:834-841.
15. Cram, D. S., N. Fiscaro, R. L. Coppel, S. Whittingham, and L. C. Harrison. 1990. Mapping of multiple B cell epitopes on the 70-kilodalton autoantigen of the U1 ribonucleoprotein complex. *J. Immunol.* 145:2962-2966.
16. McNeilage, L. J., E. M. Macmillan, and S. F. Whittingham. 1990. Mapping of epitopes on the La (SS-B) autoantigen of primary Sjogren's syndrome: identification of a cross-reactive epitope. *J. Immunol.* 145:3829-3835.
17. Van de Rijn, I., J. B. Zabriskie, and M. McCarty. 1977. Group A streptococcal antigens cross reactive with myocardium. Purification of heart reactive

- antibody and isolation and characterization of the streptococcal antigen. *J. Exp. Med.* 146:579-599.
18. Hudson, L. 1985. Autoimmune phenomena in chronic Chagasic cardiopathy. *Parasitol. Today.* 1:6-9.
19. Khoury, E. L., V. Ritacco, P. M. Cossio, R. P. Laguens, A. Szarfman, C. Diez, and R. M. Avana. 1979. Circulating antibodies to peripheral nerve in American trypanosomiasis (Chagas disease). *Clin. Exp. Immunol.* 36:8-15.
20. Query, C. C., and J. D. Keene. 1987. A human autoimmune protein associated with U1 RNA contains a region of homology that is cross-reactive with retroviral p30^{gag} protein. *Cell.* 51:211-220.
21. Maul, G. G., S. A. Jimenez, E. Riggs, and D. Ziemnicka-Kotunia. 1989. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I. *Proc. Natl. Acad. Sci. USA.* 86:8492-8496.
22. Guldner, H. H., H. J. Netter, C. Szosteki, E. Jaeger, and H. Will. 1990. Human anti-p68 autoantibodies recognise a common epitope of U1 RNA containing small nuclear ribonucleoprotein and influenza B virus. *J. Exp. Med.* 171:819-829.
23. Kohsaka, H., K. Yamamoto, H. Fujii, H. Miura, N. Miyasaka, K. Nishioka, and T. Miyamoto. 1990. Fine epitope mapping of the human SS-B/La protein. Identification of a distinct autoepitope homologous to a viral gag polyprotein. *J. Clin. Invest.* 85:1566-1574.
24. Garry, R. F. 1990. Extensive antigen mimicry by retrovirus capsid proteins. *AIDS Res. and Hum. Retroviruses.* 6:1361-1362.
25. Saiki, R. K., D. H. Gelford, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Hora, R. B. Mullis, and H. A. Erlich. 1988. Primer directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science (Wash. DC).* 239:487-491.
26. Chambers, J. C., D. Kenan, B. J. Martin, and J. D. Keene. 1988. Genomic structure and amino acid sequence domains of the human La autoantigen. *J. Biol. Chem.* 263:18043-18051.
27. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione-S-transferase. *Gene.* 67:31-40.
28. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature. (Lond).* 227:680-685.
29. McNeilage, L. J., S. Whittingham, I. Jack, and I. R. Mackay. 1985. Molecular analysis of the RNA and protein components recognised by anti-La (SS-B) autoantibodies. *Clin. Exp. Immunol.* 62:685-695.
30. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA.* 74:5463-5467.
31. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and J. R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 143:265-275.
32. Ramsden, D. A., J. Chen, F. W. Miller, V. Misener, R. M. Bernstein, K. A. Siminovitch, and F. W. L. Tsui. 1989. Epitope mapping of the cloned human autoantigen, histidyl tRNA synthetase. Analysis of the myositis-associated anti-Jo-1 autoimmune response. *J. Immunol.* 143:2267-2272.
33. Boire, G., and J. Craft. 1989. Biochemical and immunological heterogeneity of the Ro ribonucleoprotein particles. Analysis with sera specific for the Ro^{hY3} particle. *J. Clin. Invest.* 84:270-279.
34. Rader, M. D., C. Coddling, and M. Reichlin. 1989. Differences in the fine specificity of anti-Ro (SS-A) in relation to the presence of other precipitating autoantibodies. *Arthritis Rheum.* 32:1563-1571.
35. Huff, J. P., G. Roos, G. L. Peebles, R. Houghten, K. F. Sullivan, and E. M. Tan. 1990. Insights into native epitopes of proliferating cell nuclear antigen using recombinant DNA protein products. *J. Exp. Med.* 172:419-429.
36. Reeves, W. H., A. Pierani, A., C-H. Chou, T. Ng, C. Nicastrì, R. G. Roeder, and Z. M. Sthoeger. 1991. Epitopes of the p70 and p80 (Ku) lupus autoantigens. *J. Immunol.* 146:2678-2686.
37. Geysen, H. M., S. J. Rodda, and T. J. Mason. 1986. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. *Mol. Immunol.* 23:709-715.